This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Men's Health  • Cardiovascular System, Other  • Cardiovascular System  • Endocrine Diseases, Other  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Association Between Resistant Hypertension, Aldosterone, and Persistent Intravascular Volume Expansion

Krishna K. Gaddam, MD; Mari K. Nishizaka, MD; Monique N. Pratt-Ubunama, MD; Eduardo Pimenta, MD; Inmaculada Aban, PhD; Suzanne Oparil, MD; David A. Calhoun, MD

Arch Intern Med. 2008;168(11):1159-1164.

Background  Resistant hypertension is a common clinical problem and greatly increases the risk of target organ damage.

Methods  We evaluated the characteristics of 279 consecutive patients with resistant hypertension (uncontrolled despite the use of 3 antihypertensive agents) and 53 control subjects (with normotension or hypertension controlled by using 2 antihypertensive medications). Participants were prospectively examined for plasma aldosterone concentration, plasma renin activity, aldosterone to renin ratio, brain-type natriuretic peptide, atrial natriuretic peptide, and 24-hour urinary aldosterone (UAldo), cortisol, sodium, and potassium values while adhering to a routine diet.

Results  Plasma aldosterone (P < .001), aldosterone to renin ratio (P < .001), 24-hour UAldo (P = .02), brain-type natriuretic peptide (P = .007), and atrial natriuretic peptide (P = .001) values were higher and plasma renin activity (P = .02) and serum potassium (P < .001) values were lower in patients with resistant hypertension vs controls. Of patients with resistant hypertension, men had significantly higher plasma aldosterone (P = .003), aldosterone to renin ratio (P = .02), 24-hour UAldo (P < .001), and urinary cortisol (P < .001) values than women. In univariate linear regression analysis, body mass index (P = .01), serum potassium (P < .001), urinary cortisol (P < .001), urinary sodium (P = .02), and urinary potassium (P < .001) values were correlated with 24-hour UAldo levels. Serum potassium (P = .001), urinary potassium (P < .001), and urinary sodium (P = .03) levels were predictors of 24-hour UAldo levels in multivariate modeling.

Conclusions  Aldosterone levels are higher and there is evidence of intravascular volume expansion (higher brain-type and atrial natriuretic peptide levels) in patients with resistant hypertension vs controls. These differences are most pronounced in men. A significant correlation between 24-hour urinary aldosterone levels and cortisol excretion suggests that a common stimulus, such as corticotropin, may underlie the aldosterone excess in patients with resistant hypertension.

Author Affiliations: Vascular Biology and Hypertension Program (Drs Gaddam, Nishizaka, Pratt-Ubunama, Pimenta, Oparil, and Calhoun) and Department of Biostatistics, School of Public Health (Dr Aban), University of Alabama at Birmingham.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

In This Issue of Archives of Internal Medicine
Arch Intern Med. 2008;168(11):1134.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of Dietary Sodium Reduction on Blood Pressure in Subjects With Resistant Hypertension: Results From a Randomized Trial
Pimenta et al.
Hypertension 2009;54:475-481.
ABSTRACT | FULL TEXT  

Aldosterone, a vasculotoxic agent--novel functions for an old hormone
Ritz and Tomaschitz
Nephrol Dial Transplant 2009;24:2302-2305.
FULL TEXT  

Narrative Review: The Emerging Clinical Implications of the Role of Aldosterone in the Metabolic Syndrome and Resistant Hypertension
Sowers et al.
ANN INTERN MED 2009;150:776-783.
ABSTRACT | FULL TEXT  

A role for single-pill triple therapy in hypertension
Elijovich and Laffer
Ther Adv Cardiovasc Dis 2009;3:231-240.
ABSTRACT